| Oxervate (U.S.N.L.M.) | ||
|---|---|---|
| Dosing | 1 drop 6 times a day at 2 hour intervals for eight weeks | |
| Chem Specs | cenegermin-bkbj 0.002% | |
| Quantities | Weekly Vial Carton (7 multiple-dose vials). Delivery System Kit (7 vial adapters, 42 pipettes, 42 sterile disinfectant wipes, a Dose Recording Card). |
|
| Cost | $29,000 (8 week supply) | |
| Class | Neurotrophin. Recombinant nerve growth factor (NGF). | |
| Action | Replicates action of endogenous NGF controlling neurotransmitter and neuropeptide synthesis. | |
| Usage | Indicated for the treatment of neurotrophic keratitis. | |
| NGF influences the neuronal plasticity in the adult nervous system affecting innervation density, axonal terminal sprouting, and dendrite arborization. |
||
| Contraindications | None | |
| Pediatric use | Safety and effectiveness established in pediatric patients age 2 and older. | |
| Pregnancy | Administration to pregnant rats or rabbits during organogenesis did not produce adverse fetal effects at clinically relevant doses. |
|
| Contact lenses should be removed for 15 minutes when applying Oxervate. | ||
| Included instructions describe a 19 step application procedure to be followed 6 times a day. "bkbj" refers to a manufacturer code used during development. |
||